Genesis Therapeutics Inc.

About Genesis Therapeutics Inc.

Genesis Therapeutics applies deep learning and molecular simulations to create small-molecule drugs for previously undruggable targets. Founded in 2019 by Stanford researchers, the company integrates neural networks, physics-based modeling, and large-scale compute to design potent, selective compounds. Programs span oncology, immunology, and rare diseases; partnerships with Genentech, Eli Lilly, and others accelerate development. Headquarters in Burlingame, California, with laboratories in San Diego and an interdisciplinary team of AI scientists, chemists, and biologists.